论文部分内容阅读
头孢三嗪噻肟(ceftriaxone)是一种新型的头孢菌素,经体外试验证实对细菌性脑膜炎(以下简称菌脑)的三种主要病原,有很高的抗菌活性。为了比较单用头孢三嗪噻肟和并用氨苄青霉素与氯霉素治疗菌脑的效果,作者作了一次随机的前瞻性对照研究。78例菌脑病人(男性42例,女性36例;年龄在1岁以下51例)中,54例的病原为b型流感嗜血杆菌,9例为链球菌,9例为脑膜炎球菌,6例未检获病原。随机将病人分为两组:试验组39例,头孢三嗪噻肟静脉注
Ceftriaxone is a new type of cephalosporin. It has been proved in vitro to have high antibacterial activity against the three major pathogens of bacterial meningitis (hereinafter referred to as bacterial brain). To compare the efficacy of cefotaxime alone with ampicillin and chloramphenicol in the treatment of bacterial brain, the authors made a prospective randomized controlled study. Of the 78 patients with bacteremic brain disease (42 males and 36 females and 51 under the age of 1), the pathogen of 54 cases was Haemophilus influenzae b, 9 were Streptococcus, 9 were meningococci, 6 Cases did not seized the pathogen. Patients were randomly divided into two groups: experimental group 39 cases, cefotiam thiooxin intravenous injection